Every year, 31,230 @entity1 and @entity1 are diagnosed with @entity14 , and up to 60% of these will ultimately develop @entity1442 . However, there is little information to identify which @entity1 are most likely to benefit from palliative chemotherapy. This analysis is unique in evaluating how the site of @entity3 influences response and survival. A database of 497 @entity1 treated within randomized clinical trials using @entity1487 (5FU)-based chemotherapy at the Royal Marsden Hospital was analysed. The potential for site of @entity3 as a predictive variable for response to chemotherapy and survival was examined, in addition to other clinical parameters. The presence of liver @entity3 was a better predictor for overall response than either performance status or number of metastatic sites on presentation. Probability of response was significantly decreased by a raised serum @entity787 ( @entity787 ) and presence of peritoneal @entity3 . In liver @entity3 , a normal serum albumin was as significant a predictor for response as good performance status. The most important predictor for survival was initial performance status. The number of metastatic sites on presentation had no influence on survival. Site of @entity3 can predict for response to 5FU-based chemotherapy and @entity1 should be stratified according to the involved site of @entity3 in the future.

Influence of metastatic site as an additional predictor for response and outcome in advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity787 :: ('1084', 'Gene') :: ['CEA', 'carcinoembryonic antigen'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinoma'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-Fluorouracil']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal carcinoma']
